Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

367
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
367
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

213
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
213
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

2.9K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
2.9K
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

804
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
804
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

878
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
878
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

12.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
12.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From the perspective of prolactin: a view on obesity.

Frontiers in endocrinology·2026
Same author

Integrin α2: mode of regulation and functioning in the metastatic cancer cascade.

Journal of translational medicine·2026
Same author

Effect of traditional Chinese medicine on disturbances of untargeted metabolomics in ulcerative colitis.

Journal of ethnopharmacology·2026
Same author

Identification of a key smooth muscle cell subset driving ischemic cardiomyopathy progression through single-cell RNA sequencing.

Scientific reports·2025
Same author

Single-cell RNA sequencing reveals the potential role of Postn(+) fibroblasts in promoting the progression of myocardial fibrosis after myocardial infarction.

Scientific reports·2025
Same author

Pharmacological potential of natural medicine Astragali Radix in treating intestinal diseases.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2024

Related Experiment Video

Updated: Jan 15, 2026

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

7.1K

Decoding post-myocardial infarction coronary microvascular dysfunction: The SP1-driven STAT3/KCa3.1/eNOS protective

Zhen Wang1, Yong Wang1, Yan Cheng1

  • 1Department of Cardiology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.

Cytojournal
|October 13, 2025
PubMed
Summary

Transcription factor SP1 reverses microvascular dysfunction after myocardial infarction (MI) by activating the STAT3/KCa3.1/eNOS pathway. This finding offers new therapeutic strategies for cardiovascular diseases.

Keywords:
HomocysteineMyocardial infarctionSP1Signal transducer and activator of transcription 3/conductance calcium-activated potassium channel protein 4/endothelial nitric oxide synthase pathway

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.0K
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.3K

Related Experiment Videos

Last Updated: Jan 15, 2026

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

7.1K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.0K
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

4.3K

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Cellular Physiology

Background:

  • Coronary microvascular dysfunction post-myocardial infarction (MI) impairs cardiac repair.
  • Hyperhomocysteinemia (HHcy) exacerbates microvascular damage after MI.
  • The role of transcription factor SP1 in HHcy-induced microvascular dysfunction post-MI is not fully understood.

Purpose of the Study:

  • To investigate the mechanism of SP1 in reversing HHcy-induced microvascular dysfunction after MI.
  • To elucidate the signaling pathway involved in SP1-mediated protection.

Main Methods:

  • Utilized HHcy mouse and human coronary artery endothelial cell (HCAEC) models.
  • Assessed cardiac microvascular perfusion and protein expression via Western blot.
  • Employed specific inhibitors (L-NAME, Stattic) to validate the STAT3/KCa3.1/eNOS pathway.

Main Results:

  • SP1 significantly improved microvascular function and angiogenesis in HHcy mice post-MI.
  • SP1 activated the STAT3/KCa3.1/eNOS signaling pathway, crucial for endothelial nitric oxide synthase (eNOS) activity.
  • SP1 protected HCAECs from homocysteine and hypoxia-induced damage via this pathway.

Conclusions:

  • SP1 reverses HHcy-induced microvascular dysfunction post-MI by activating the STAT3/KCa3.1/eNOS pathway.
  • This study provides novel insights into the molecular mechanisms of post-MI cardiovascular complications.
  • SP1 represents a potential therapeutic target for cardiovascular disease treatment.